Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
Osimertinib is the standard of care for the first-line treatment of EGFR-mutated NSCLC. We report a case of a 52-year-old woman who developed life-threatening myopathy because of treatment with osimertinib. Limited instances of myositis have been previously reported in the literature; however, none...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364321001193 |
| _version_ | 1828127339598315520 |
|---|---|
| author | Fionnuala Crowley, MB BCh BAO Bailey G. Fitzgerald, MD Aarti S. Bhardwaj, MD Irine Siraj, MD Cardinale Smith, MD, PhD |
| author_facet | Fionnuala Crowley, MB BCh BAO Bailey G. Fitzgerald, MD Aarti S. Bhardwaj, MD Irine Siraj, MD Cardinale Smith, MD, PhD |
| author_sort | Fionnuala Crowley, MB BCh BAO |
| collection | DOAJ |
| description | Osimertinib is the standard of care for the first-line treatment of EGFR-mutated NSCLC. We report a case of a 52-year-old woman who developed life-threatening myopathy because of treatment with osimertinib. Limited instances of myositis have been previously reported in the literature; however, none have resulted in life-threatening oropharyngeal and respiratory muscle weakness as seen in this case. Care should be taken in administering osimertinib concurrently with other medications metabolized by the CYP3A4 system, and ongoing work to identify patients at risk for severe reactions is necessary. The use of routine creatinine phosphokinase monitoring should be considered as part of oncologic management. |
| first_indexed | 2024-04-11T15:48:55Z |
| format | Article |
| id | doaj.art-3037aed886054078908381c3d5bc2233 |
| institution | Directory Open Access Journal |
| issn | 2666-3643 |
| language | English |
| last_indexed | 2024-04-11T15:48:55Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj.art-3037aed886054078908381c3d5bc22332022-12-22T04:15:26ZengElsevierJTO Clinical and Research Reports2666-36432022-01-0131100260Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case ReportFionnuala Crowley, MB BCh BAO0Bailey G. Fitzgerald, MD1Aarti S. Bhardwaj, MD2Irine Siraj, MD3Cardinale Smith, MD, PhD4Department of Internal Medicine, Mount Sinai Morningside West, New York, New YorkDivision of Hematology/Oncology, Mount Sinai Hospital, New York, New York; Corresponding author. Address for correspondence: Bailey G. Fitzgerald, MD, Icahn School of Medicine at Mount Sinai,Department of Hematology and Medical Oncology, One Gustave Levy Place, New York, NY 10029.Division of Hematology/Oncology, Mount Sinai Hospital, New York, New YorkDepartment of Neurology, Mount Sinai Hospital, New York, New YorkDivision of Hematology/Oncology, Mount Sinai Hospital, New York, New YorkOsimertinib is the standard of care for the first-line treatment of EGFR-mutated NSCLC. We report a case of a 52-year-old woman who developed life-threatening myopathy because of treatment with osimertinib. Limited instances of myositis have been previously reported in the literature; however, none have resulted in life-threatening oropharyngeal and respiratory muscle weakness as seen in this case. Care should be taken in administering osimertinib concurrently with other medications metabolized by the CYP3A4 system, and ongoing work to identify patients at risk for severe reactions is necessary. The use of routine creatinine phosphokinase monitoring should be considered as part of oncologic management.http://www.sciencedirect.com/science/article/pii/S2666364321001193OsimertinibMyositisNSCLCEGFRCase report |
| spellingShingle | Fionnuala Crowley, MB BCh BAO Bailey G. Fitzgerald, MD Aarti S. Bhardwaj, MD Irine Siraj, MD Cardinale Smith, MD, PhD Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report JTO Clinical and Research Reports Osimertinib Myositis NSCLC EGFR Case report |
| title | Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report |
| title_full | Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report |
| title_fullStr | Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report |
| title_full_unstemmed | Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report |
| title_short | Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report |
| title_sort | life threatening myositis in a patient with egfr mutated nsclc on osimertinib case report |
| topic | Osimertinib Myositis NSCLC EGFR Case report |
| url | http://www.sciencedirect.com/science/article/pii/S2666364321001193 |
| work_keys_str_mv | AT fionnualacrowleymbbchbao lifethreateningmyositisinapatientwithegfrmutatednsclconosimertinibcasereport AT baileygfitzgeraldmd lifethreateningmyositisinapatientwithegfrmutatednsclconosimertinibcasereport AT aartisbhardwajmd lifethreateningmyositisinapatientwithegfrmutatednsclconosimertinibcasereport AT irinesirajmd lifethreateningmyositisinapatientwithegfrmutatednsclconosimertinibcasereport AT cardinalesmithmdphd lifethreateningmyositisinapatientwithegfrmutatednsclconosimertinibcasereport |